siRNA silencing of filovirus gene expression

Details siRNA silencing of filovirus gene expression siRNA silencing of filovirus gene expression

2006-10-20

2010-11-23

Chong, Kimberly (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S024310, C536S024100, C435S006120, C435S325000, C435S375000, C514S04400A

Reexamination Certificate

active

07838658

ABSTRACT:
The present invention provides siRNA molecules that target Filovirus gene expression and methods of using such siRNA molecules to silence Filovirus gene expression. The present invention also provides nucleic acid-lipid particles that target Filovirus gene expression comprising an siRNA that silences Filovirus gene expression, a cationic lipid, and a non-cationic lipid.

REFERENCES:
patent: 5705385 (1998-01-01), Bally et al.
patent: 5976567 (1999-11-01), Wheeler et al.
patent: 5981501 (1999-11-01), Wheeler et al.
patent: 6534484 (2003-03-01), Wheeler et al.
patent: 6586410 (2003-07-01), Wheeler et al.
patent: 6680068 (2004-01-01), Campbell et al.
patent: 6815432 (2004-11-01), Wheeler et al.
patent: 6858224 (2005-02-01), Wheeler et al.
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2004/0142892 (2004-07-01), Finn et al.
patent: 2004/0253723 (2004-12-01), Tachas et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0064595 (2005-03-01), MacLachlan et al.
patent: 2005/0282188 (2005-12-01), Haeberli et al.
patent: 2006/0008910 (2006-01-01), MacLachlan et al.
patent: 2006/0205693 (2006-09-01), Stein et al.
patent: 2007/0135372 (2007-06-01), MacLachlan et al.
patent: WO 02/087541 (2002-11-01), None
patent: WO 03/097805 (2003-11-01), None
patent: WO 2004/065546 (2004-08-01), None
patent: WO 2004/110499 (2004-12-01), None
patent: WO 2005/007196 (2005-01-01), None
patent: WO 2005/026372 (2005-03-01), None
patent: WO 2005/120152 (2005-12-01), None
patent: WO 2005/121348 (2005-12-01), None
patent: WO 2006/074546 (2006-07-01), None
patent: WO 2007/051303 (2007-05-01), None
Arpicco, S., et al., “Preparation and Characterization of Novel Cationic Lipids Developed for Gene Transfection,” Proceed. Int'l Symp. Control. Rel. Bioact. Mater. (Controlled Release Society, Inc.), 1999, vol. 26, pp. 759-760.
Arpicco, S., et al., “Synthesis, characterization and transfection activity of new saturated and unsaturated cationic lipids,” IL Farmaco, 2004, vol. 59, pp. 869-878.
Beale, G., et al., “Gene Silencing Nucleic Acids Designed by Scanning Arrays: Anti-EGFR Activity of siRNA, Ribozyme and DNA Enzymes Targeting a Single Hybridization-accessible Region using the Same Delivery System,” Journal of Drug Targeting, 2003, vol. 11, No. 7, pp. 449-456.
Cevc, G., “How Membrane Chain-Melting Phase-Transition Temperature is Affected by the lipid Chain Asymmetry and Degree of Unsaturation: An Effective Chain-Length Model,” Biochemistry, 1991, vol. 30, pp. 7186-7193.
Enterlein, Sven, et al., “VP35 Knockdown Inhibits Ebola Virus Amplification and Protects against Lethal Infection in Mice,” Antimicrobial Agents and Chemotherapy, 2006, vol. 50, No. 3, pp. 984-993.
Feldmann, Heinz, et al., “Therapy and prophylaxis of Ebola virus infections,” Current Opinion in Investigational Drugs, 2005, vol. 6, No. 8, pp. 823-830.
Fowler, Trent, et al., “Inhibition of Marburg virus protein expression and viral release by RNA interference,” Journal of General Virology, 2005, vol. 86, pp. 1181-1188.
Geisbert, Thomas W., et al., “Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge Is Conferred by RNA Interference,” The Journal of Infectious Diseases, 2006, vol. 193, No. 12, pp. 1650-1657.
Jiang, L., et al., “Comparison of protein precipitation methods for sample preparation prior to proteomic analysis,” Journal of Chromatography A, 2004, vol. 1023, pp. 317-320.
Keough, K., “Influence of chain unsaturation and chain position on thermotropism and intermolecular interactions in membranes,” Biochem. Soc. Transactions, 1990, vol. 18, No. 5, pp. 835-837.
Paul, C., et al., “Effective expression of small interfering RNA in human cells,” Nature Biotech., 2002, vol. 20, pp. 505-508.
Spagnou, S., et al., “Lipidic Carriers of siRNA: Differences in the Formulation, Cellular Uptake, and Delivery with Plasmid DNA,” Biochemistry, 2004, vol. 43, pp. 13348-13356.
Warfield, Kelly L., et al., “Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers,” PLoS Pathogens, 2006, vol. 2, No. 1, pp. 0005-0012.
Reynolds, A., et al., “Rational siRNA design for RNA interference,” Nat. Biotech., 2004, vol. 22, No. 3, pp. 326-330.

Affiliated with

Also associated with

Rating

siRNA silencing of filovirus gene expression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with siRNA silencing of filovirus gene expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and siRNA silencing of filovirus gene expression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4230153